Gian Rizzardi - MolMed S Insider

4HW -- Germany Stock  

EUR 0.43  0.001  0.23%

Director Research & Development
Dr. Gian Paolo Rizzardi serves as General Manager at Molecular Medicine S.p.A. He was Director of Research Development of Molecular Medicine S.p.A. from July 2011. He has more than 15 years experience in research on immunotherapeutic strategies, particularly in the areas of HIVAIDS and infectious diseases he contributed to the HIVAIDS field with important studies on HIV immunepathogenesis and with the design and development of immunomodulatory therapeutic strategies. Working at the Company, he also developed experience in the fields of tumor homing peptides and of vascular targeting agents. He is Author of more than 60 peerreviewed publications and, together with Mr. Giuseppe Pantaleo, won the Pfizer Prize for research in infectious diseases in 1999. He has served as University Lecturer of Internal Medicine, Immunology, Infectious Disease and Biotechnology in Italy, Switzerland and the United States. He gained a Doctorate of Medicine in Medicine from Universita degli Studi di Milano in 1991.
Age: 50  Director Since 2015  Ph.D    
39 02 21 27 71  http://www.molmed.com

Management Efficiency

The company has return on total asset (ROA) of (11.32) % which means that it has lost $11.32 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (36.33) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 3.9 implying the company greatly relies on financing operations through barroing. MolMed S p A has Current Ratio of 1.94 which is within standard range for the sector.

Similar Executives

Entity Summary

MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. MolMed S.p.A. was founded in 1996 and is headquartered in Milan, Italy. MolMed S operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange.MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. It is located in Via Olgettina, 58 and employs 23 people.

MolMed S p Leadership Team

Gian Rizzardi, Director, Ph.D
Marina Bue, Director
Didier Trono, Director
Silvia Pisante, Executive
Mario Masciocchi, Director
Carlo Incerti, Director
Raffaella Ruggiero, Director
Holger Neecke, Director
Luca Alberici, Executive
Maurizio Tassi, Director
Daniele Pieraccioli, Director, Ph.D
Alberto Carletti, Director
Laura Ferro, Director
Marco Dieci, Director, Ph.D
Catia Traversari, Director, Ph.D
Lorenzo Salieri, Director
Elizabeth Robinson, Director
Riccardo Palmisano, CEO
Sabina Grossi, Director, Ph.D
Alfredo Messina, Director
Monica Masolo, Director
Germano Carganico, Executive, Ph.D
Claudio Bordignon, Chairman, Ph.D
Gianluigi Fiorendi, Director
Andrea Quaglino, Director
Khalid Islam, Director, Ph.D
Laura Villa, Director
Cynthia Giuliani, Director
Antonio Lambiase, Director, Ph.D
Marco Manoni, Director
Tiziano Andreoli, Director

Stock Performance Indicators

Current Sentiment - 4HW

MolMed S p Investor Sentiment
Macroaxis portfolio users are unresponsive in their sentiment towards investing in MolMed S p A. What is your trading attitude regarding investing in MolMed S p A? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Thematic Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Thematic Ideas
Explore Investing Ideas  
Check also Trending Equities. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.